The pro-inflammatory marker soluble suppression of tumorigenicity-2 (ST2) is reduced especially in diabetic morbidly obese patients undergoing bariatric surgery.
Bariatric surgery
Diabetes
Obesity
sST2
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
26 02 2020
26 02 2020
Historique:
received:
03
12
2019
accepted:
13
02
2020
entrez:
27
2
2020
pubmed:
27
2
2020
medline:
26
8
2020
Statut:
epublish
Résumé
High soluble suppression of tumorigenicity-2 (sST2) is a marker of poor prognosis in chronic inflammatory conditions. ST2 and its ligand interleukin (IL)-33 are elevated in adipose tissue of obese individuals. We aimed to evaluate circulating sST2 and IL-33 as possible markers of metabolic benefit in morbidly overweight patients after Roux-en-Y gastric bypass (RYGB) bariatric surgery. sST2, IL-33, high sensitive IL-6, high sensitive C-reactive protein (hsCRP), leptin, cholesterol metabolism and liver parameters were measured in 80 morbidly obese individuals before and 1 year after bariatric surgery. sST2 was higher (P = 0.03) in diabetics as compared to individuals without diabetes. Baseline sST2 was also higher in males than in females (P= 0.0002). One year after bariatric surgery, sST2 levels were decreased (median 120, IQR 59-176 pg/mL) as compared to sST2 before surgery (median 141, IQR 111-181, P = 0.0024), and the diabetic group showed most pronounced reduction in sST2 (P = 0.0016). An association was found between sST2 and liver function parameters before and after bariatric surgery, and between baseline sST2 and total cholesterol, triglyceride, total low density lipoprotein (LDL), small dense LDL, Apolipoprotein B as well as with small dense high density lipoproteins (HDL). In the subgroup of diabetic patients positive correlation between IL-33 and sST2 (r = 0.44, P = 0.05) was noticed. Circulating sST2 is associated with markers of liver functions and lipid metabolism in severely obese patients and a reduction of sST2 was shown after successful bariatric surgery, most prominently in diabetic patients.
Sections du résumé
BACKGROUND
High soluble suppression of tumorigenicity-2 (sST2) is a marker of poor prognosis in chronic inflammatory conditions. ST2 and its ligand interleukin (IL)-33 are elevated in adipose tissue of obese individuals. We aimed to evaluate circulating sST2 and IL-33 as possible markers of metabolic benefit in morbidly overweight patients after Roux-en-Y gastric bypass (RYGB) bariatric surgery.
METHODS
sST2, IL-33, high sensitive IL-6, high sensitive C-reactive protein (hsCRP), leptin, cholesterol metabolism and liver parameters were measured in 80 morbidly obese individuals before and 1 year after bariatric surgery.
RESULTS
sST2 was higher (P = 0.03) in diabetics as compared to individuals without diabetes. Baseline sST2 was also higher in males than in females (P= 0.0002). One year after bariatric surgery, sST2 levels were decreased (median 120, IQR 59-176 pg/mL) as compared to sST2 before surgery (median 141, IQR 111-181, P = 0.0024), and the diabetic group showed most pronounced reduction in sST2 (P = 0.0016). An association was found between sST2 and liver function parameters before and after bariatric surgery, and between baseline sST2 and total cholesterol, triglyceride, total low density lipoprotein (LDL), small dense LDL, Apolipoprotein B as well as with small dense high density lipoproteins (HDL). In the subgroup of diabetic patients positive correlation between IL-33 and sST2 (r = 0.44, P = 0.05) was noticed.
CONCLUSIONS
Circulating sST2 is associated with markers of liver functions and lipid metabolism in severely obese patients and a reduction of sST2 was shown after successful bariatric surgery, most prominently in diabetic patients.
Identifiants
pubmed: 32101157
doi: 10.1186/s12933-020-01001-y
pii: 10.1186/s12933-020-01001-y
pmc: PMC7045735
doi:
Substances chimiques
Biomarkers
0
IL1RL1 protein, human
0
IL33 protein, human
0
Inflammation Mediators
0
Interleukin-1 Receptor-Like 1 Protein
0
Interleukin-33
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
26Références
Obes Surg. 2018 Sep;28(9):2804-2810
pubmed: 29693219
Thromb Haemost. 2013 Oct;110(4):641-50
pubmed: 23846791
J Exp Med. 2013 Mar 11;210(3):535-49
pubmed: 23420878
Cardiovasc Diabetol. 2019 Mar 19;18(1):36
pubmed: 30890169
Front Immunol. 2017 Nov 15;8:1512
pubmed: 29187850
Nature. 2015 Mar 12;519(7542):242-6
pubmed: 25533952
World J Gastroenterol. 2016 Nov 28;22(44):9706-9717
pubmed: 27956794
Obes Surg. 2020 Feb;30(2):391-400
pubmed: 31728904
J Clin Invest. 2017 Jan 3;127(1):1-4
pubmed: 28045402
Arterioscler Thromb Vasc Biol. 2011 Sep;31(9):2080-9
pubmed: 21737781
Int J Obes (Lond). 2013 May;37(5):658-65
pubmed: 22828942
Bone Marrow Transplant. 2015 Mar;50(3):402-10
pubmed: 25531283
Diabetol Metab Syndr. 2017 May 25;9:41
pubmed: 28559931
Cytokine. 2018 Mar;103:109-113
pubmed: 28974430
Eur Heart J. 2009 Jun;30(12):1516-24
pubmed: 19380349
Am J Cardiol. 2015 Apr 2;115(7 Suppl):70B-5B
pubmed: 25670638
Cardiovasc Res. 2018 Oct 1;114(12):1578-1594
pubmed: 29982301
Cardiovasc Diabetol. 2011 Nov 21;10:101
pubmed: 22104207
J Am Heart Assoc. 2017 Feb 18;6(2):
pubmed: 28214792
Circ Res. 2010 Sep 3;107(5):650-8
pubmed: 20634488
J Clin Invest. 2007 Jun;117(6):1538-49
pubmed: 17492053
Can J Cardiol. 2018 May;34(5):595-604
pubmed: 29459241
Diabetes Care. 2018 Jan;41(Suppl 1):S65-S72
pubmed: 29222378
Arterioscler Thromb Vasc Biol. 2012 Dec;32(12):e149-60
pubmed: 23065828
Cytokine. 2014 Jun;67(2):65-70
pubmed: 24725541
Circ Res. 2016 May 27;118(11):1844-55
pubmed: 27230645
Clin Chem. 2001 Feb;47(2):266-74
pubmed: 11159775
Heart. 2016 Oct 15;102(20):1633-9
pubmed: 27220692
Diabetes Res Clin Pract. 2016 Aug;118:140-5
pubmed: 27371779
Sci Rep. 2016 May 04;6:25171
pubmed: 27142573
Curr Opin Endocrinol Diabetes Obes. 2016 Oct;23(5):373-8
pubmed: 27455515
PLoS One. 2012;7(10):e47830
pubmed: 23112853
PLoS One. 2014 Apr 21;9(4):e95055
pubmed: 24751794
Clin Chim Acta. 2009 Nov;409(1-2):33-40
pubmed: 19699192
Biochem Biophys Res Commun. 2009 Jun 19;384(1):105-9
pubmed: 19393621
Cardiovasc Diabetol. 2018 Aug 31;17(1):122
pubmed: 30170598
Clin Med (Lond). 2018 Jun;18(3):245-250
pubmed: 29858436
Obes Surg. 2017 Jan;27(1):2-21
pubmed: 27957699
Int J Mol Sci. 2019 Apr 30;20(9):
pubmed: 31052333
Clin Chem. 2012 Dec;58(12):1673-81
pubmed: 23065477
J Cell Mol Med. 2018 Apr;22(4):2422-2429
pubmed: 29397580
Immunol Rev. 2018 Jan;281(1):154-168
pubmed: 29247993
PLoS One. 2015 Apr 07;10(4):e0123367
pubmed: 25849089
Diabetes Care. 2018 Jan;41(Suppl 1):S13-S27
pubmed: 29222373
J Thromb Thrombolysis. 2019 Jan;47(1):51-56
pubmed: 30259314
Clin Chem Lab Med. 2011 Sep;49(9):1515-8
pubmed: 21663467
Cardiovasc Diabetol. 2018 Dec 29;17(1):161
pubmed: 30594184
Immunity. 2005 Nov;23(5):479-90
pubmed: 16286016